I am not building this
from the outside.
Concussions since elementary-school football and middle-school lacrosse. Twenty-plus times in my career I took a hit, felt my brain shake and my vision vibrate, and kept playing anyway.
I know the loopholes because I used them.
I faked impact tests. I gamed the balance and Sway screens. So did people I played with. Not because anyone was negligent, but because the system asks an athlete who loves the game to self-report the one thing that takes them out of it. That is a structural problem, not an athletic-trainer problem.
I live with the result. Daily headaches, a history of mild and moderate TBIs. I understand this market from the inside.
Spring 2026 I took another one. I stepped away from the game I love, for good, and went all in on Chronic Trace. This is no longer something I do on the side. It is the whole thing.
We need something cheap, usable by anyone, available right there on the sideline, and impossible to fake. That is Chronic Trace. Let us make a difference.
Invest in the laboratory
test for the brain.
Chronic Trace is opening to the people who want to back it. Reserve a non-binding allocation now. When the offering goes live through a registered platform, reserved investors hear first.
- Stage
- Research-stage SaMD
- Offering
- Regulation Crowdfunding (planned)
- Platform
- Registered funding portal (planned)
- This page
- Non-binding reservation
No money is being solicited or accepted. No securities are being sold on this page.
We are not selling the future.
We are running it.
The platform vision is real and patented. The deck does not lead with it. What follows is what is live, in the field, and measurable right now.
Biomarker domains scored on commodity hardware: postural sway, oculomotor, cognitive, reaction time, autonomic.
U.S. mixed-martial-arts (sub-concussive exposure between competition windows) and Ukraine (combat-zone, civilian-displacement, blast and impact).
Recorded and transcribed alongside captures. The workflow failures repeat. The data-room corpus is being built in real time.
Multi-modal involuntary fusion, manipulation-resistance, indication-specific scoring. The defensibility argument compounds with the platform, not after it.
- No FDA 510(k) yet. Submission planning is active under a pre-submission Q-Sub posture. Use of proceeds funds that path.
- No peer-reviewed validation paper of our own yet. Cohort data is being collected to support one.
- Manipulation-resistance is structurally argued and architecturally enforced. A formal sandbag-resistance study against a coached-cheater protocol is on the near-term roadmap.
- This page is testing-the-waters under planned Regulation Crowdfunding. Nothing here is an offer to sell securities.
A defensible answer to a documented gap.
Cardiology has troponin. The brain still runs on a self-report checklist. The category is wide open and the clinical need is severe.
Nine involuntary biomarker domains the user cannot consciously fake, fused through the d-CIIV methodology into one calibrated index.
Nine filed United States provisional patents that build on one another across concussion, TBI, CTE, stroke, psychiatric severity, neurodegeneration, oncologic detection, and infectious disease.
Built bottom-up across nine filed indications spanning concussion and TBI, stroke, mental health, neurodegeneration, oncology, and infectious disease. Roughly $135B near-term and $267B+ full-platform addressable by 2034, per third-party diagnostic-market research.
Hardware-agnostic capture from a commodity phone or tablet, with five independently fundable commercial channels.
Built by a founder who lived the exact failure the platform exists to fix.
Sources: Boston University CTE Center; peer-reviewed concussion sensitivity literature; third-party diagnostic-market research across traumatic brain injury, stroke, digital mental health, dementia, cancer, and infectious-disease diagnostics. Figures are public. The full bottom-up model is shared in the investor materials.
Final terms are set in the offering filing and will be disclosed there. Nothing below is an offer.
- Security type
- To be set in the offering filing
- Offering type
- Regulation Crowdfunding (planned)
- Platform
- Registered funding portal (planned)
- Price per share
- To be announced
- Pre-money valuation
- To be announced
- Minimum investment
- To be announced
- Use of proceeds
- Clinical validation, FDA submissions, and platform expansion across the patent portfolio.
Tell us you're
in.
This reserves a non-binding indication of interest. No money changes hands here. When the offering opens through a registered platform, reserved investors are contacted first with the official documents.
No money or other consideration is being solicited by this page, and if money is sent in response it will not be accepted. No offer to buy securities can be accepted, and no part of any purchase price can be received, until an offering statement is filed with and qualified by the SEC, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the qualification date. A person's indication of interest involves no obligation or commitment of any kind. Chronic Trace is a research-stage company; its platform is Software-as-a-Medical-Device in development and is not diagnostic. This communication is not an offer to sell or a solicitation of an offer to buy securities, contains forward-looking statements subject to regulatory, clinical, and commercial-execution risk, and is subject to review by counsel. Any offering will be made only through a registered intermediary and the official offering documents.